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A total of 1,527 clinically significant outpatient isolates of Streptococcus pneumoniae were prospectively
collected in 30 different U.S. medical centers between November 1994 and April 1995. Overall, 23.6% of strains
were not susceptible to penicillin, with 14.1% intermediate and 9.5% high-level resistant. The frequencies of
recovery of intermediate and high-level resistant strains varied considerably between different medical centers
and in different geographic areas. In general, intermediate and high-level penicillin resistance was most com-
mon with isolates of S. pneumoniae recovered from pediatric patients. The in vitro activities of 22 other anti-
microbial agents were assessed against this collection of isolates. Ampicillin was consistently 1 twofold dilution
less active than penicillin. Amoxicillin and amoxicillin-clavulanate were essentially equivalent to penicillin in
activity. The rank order of activity for cephalosporins was cefotaxime 5 ceftriaxone > cefpodoxime > cefu-
roxime > cefprozil> cefixime > cefaclor5 loracarbef > cefadroxil5 cephalexin. The National Committee for
Clinical Laboratory Standards [Performance Standards for Antimicrobial Susceptibility Testing, Sixth Information
Supplement (M100-S6), 1995] has established MIC breakpoints for resistance (i.e., >2 mg/ml) with three
cephalosporins versus S. pneumoniae, namely, cefotaxime, ceftriaxone, and cefuroxime. The overall percentages
of strains resistant to these three antimicrobial agents were 3, 5, and 12, respectively. The overall frequency of
resistance was 10% with all three macrolides examined in this study, clarithromycin, erythromycin, and
azithromycin. The overall percentages of chloramphenicol, tetracycline, and trimethoprim-sulfamethoxazole
resistance were 4.3, 7.5, and 18, respectively. The resistance percentages among the cephalosporins, macro-
lides, chloramphenicol, tetracycline, and trimethoprim-sulfamethoxazole were consistently higher among pen-
icillin-intermediate strains than among susceptible isolates and even higher still among organisms expressing
high-level penicillin resistance. Multiply resistant strains represented 9.1% of the organisms examined in this
study. Finally, rifampin resistance was uncommon (i.e., 0.5%), and vancomycin resistance was not detected.
The quinopristin-dalfopristin combination was consistently active at concentrations of 0.25 to 4 mg/ml, but
rates of resistance could not be determined in the absence of established interpretive criteria for MIC results.
Prior to the early 1990s, penicillin resistance remained un-
common among clinical isolates of Streptococcus pneumoniae
in the United States despite the emergence of this problem in
many other parts of the world (1, 10). In an ongoing national
surveillance program conducted by the Centers for Disease
Control through the decade of the 1980s, strains of S. pneu-
moniae that were not penicillin susceptible were recovered
infrequently, i.e., 3 to 6% (23). Furthermore, among those
strains found not to be susceptible to penicillin, nearly all were
penicillin intermediate (Peni) (i.e., penicillin MICs5 0.1 to 1.0
mg/ml). High-level resistant strains (Penr) (i.e., penicillin MICs
of $2.0 mg/ml) were extremely uncommon. These findings
were corroborated by one large independent national surveil-
lance study that characterized 487 isolates from 15 U.S. med-
ical centers in 1987 to 1988 (9). In this study, the percentages
of Peni and Penr strains were found to be 3.8 and 0.2, respec-
tively.
A major increase in the prevalence of penicillin resistance
with the pneumococcus evidently took place some time during
the early 1990s in the United States, because a national sur-
veillance study performed by Thornsberry and colleagues
which characterized 524 isolates from 17 centers during 1991
to 1992 now demonstrated an aggregate percentage of inter-
mediate and high-level resistance of 17.8%, with 15.2% Peni
and 2.6% Penr (24). One year later during 1992 to 1993, Barry
and coworkers observed even higher rates of penicillin resis-
tance in a second U.S. national surveillance study (2). Among
799 isolates from 19 U.S. medical centers, the prevalence of
Peni was 14.9%, and the prevalence of Penr was 7.3%.
The mechanism of penicillin resistance is alteration of high-
molecular-weight penicillin-binding proteins (PBPs) (11–13).
These same PBPs are also important in manifesting the activity
of other b-lactams such as the b-lactamase inhibitor combina-
tions, cephalosporins, and carbapenems. As a result, the activ-
ity of all of these agents is diminished to at least some extent
against pneumococci that are not susceptible to penicillin (2, 3,
6, 9, 12, 22). In general, only cephalosporins with high intrinsic
activity against penicillin-susceptible strains (Pens) of S. pneu-
moniae (i.e., cefotaxime, ceftriaxone, cefpodoxime, cefuroxime,
and perhaps cefprozil) retain sufficient activity against Peni
strains to be considered of value in treating infections due to
such organisms (6, 10). Only cefotaxime and ceftriaxone are
thought to be of utility in managing selected infections due to
typical penr isolates (6, 10). Of great concern are recent reports
of clinical isolates of Peni S. pneumoniae with further alter-
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ations in PBPs that express high-level resistance against cefo-
taxime and ceftriaxone (4, 7, 20).
In addition to the emergence of b-lactam resistance, isolates
of S. pneumoniae which are resistant to the macrolides, tetra-
cycline, chloramphenicol, and trimethoprim-sulfamethoxazole
(TMP-SMX) either alone or in some combination, are now
also being recovered increasingly more often from human clin-
ical material in the United States (2, 10). As was the case with
b-lactam-resistant pneumococci, multiresistant strains had
been recognized as a problem in other parts of the world prior
to their emergence in the United States (1, 8, 10).
The intent of the current multicenter national surveillance
study was to clearly define the prevalence of antimicrobial
resistance among clinical isolates of S. pneumoniae in the
United States during the winter of 1994 to 1995. Sampling was
performed prospectively in such a way as to provide large
numbers of community-acquired isolates representative of dif-
ferent geographic areas, different patient populations, and dif-
ferent infectious disease conditions.
MATERIALS AND METHODS
A total of 1,527 isolates of S. pneumoniae were collected from 30 different U.S.
medical centers between 1 November 1994 and 31 April 1995 (Table 1). In all
cases, isolates characterized in this study were recovered from consecutive
unique nonhospitalized patients. With the exception of lower respiratory tract
specimens, all isolates were obtained from specimens representative of normally
sterile body sites (see Table 3). When recovered from lower respiratory tract
specimens, only isolates of S. pneumoniae judged to be of at least probable
clinical significance were included. In contributing study centers, isolates were
subcultured onto 5% sheep blood agar plates and incubated overnight at 35 to
378C in 5 to 7% CO2. A large amount of colony growth was collected on a rayon
swab and immediately immersed in a specially devised, plastic-cap transport tube
containing 12 ml of semisolid Aimes transport medium with charcoal (Difco
Laboratories, Detroit, Mich.). Transport tubes were then shipped overnight to
the coordinating study center, the University of Massachusetts Medical Center,
where all additional analyses were performed. The recovery rate from this trans-
port system was 100%.
Isolates were frozen at 2708C in the coordinating study center until further
characterization. Following two subcultures, the identity of isolates was con-
firmed as S. pneumoniae by conventional tests and criteria. MICs were deter-
mined in Mueller-Hinton broth supplemented with 3% lysed horse blood by the
broth microdilution method recommended by the National Committee for Clin-
ical Laboratory Standards (NCCLS) (16, 17). Microdilution trays (final volume
of 100 ml per well) were inoculated with ca. 53 105 CFU/ml (final concentration)
of test organism and incubated for 22 to 24 h at 358C in ambient air prior to
determining MICs. The following 23 antimicrobial agents, obtained as laborato-
ry-grade powders from their respective manufacturers, were tested: penicillin,
ampicillin, amoxicillin, amoxicillin-clavulanate (2:1), cefotaxime, ceftriaxone,
quinopristin-dalfopristin (30:70), cephalexin, cefadroxil, cefaclor, loracarbef, cef-
prozil, cefuroxime, cefixime, cefpodoxime, erythromycin, azithromycin, clarithro-
mycin, TMP-SMX (1:19), chloramphenicol, tetracycline, rifampin, and vancomy-
cin. Twelve concentrations of each agent were tested such that off-scale results
were obtained only infrequently. S. pneumoniae ATCC 49619 and Haemophilus
influenzae ATCC 49247, ATCC 49766, and ATCC 10211 were used as controls.
Calculations of the percentages of isolates resistant to specific antimicrobial
agents were restricted to compounds for which the NCCLS has established MIC
interpretive criteria defining the resistant category for S. pneumoniae (17). These
compounds and criteria were as follows: amoxicillin, amoxicillin-clavulanate,
cefotaxime, ceftriaxone, cefuroxime, azithromycin, and vancomycin, all $2 mg/
ml; clarithromycin and erythromycin, $1 mg/ml; chloramphenicol and tetracy-
cline, $8 mg/ml; and rifampin and TMP-SMX, $4 mg/ml. The NCCLS penicillin
breakpoints of 0.1 to 1 mg/ml (intermediate category) and $2 mg/ml (resistant
category) were also employed.
RESULTS
A total of 1,527 isolates of S. pneumoniae were characterized
in this study (Table 1). Among these isolates, 216 (14.1%) were
Peni and 145 (9.5%) were Penr. The percentage of strains not
susceptible to penicillin, i.e., Peni plus Penr, varied consider-
ably among contributing study centers from a low of 2.1 at
Temple University Medical Center in Philadelphia, Pa., to a
high of 52.9 at Mt. Sinai Hospital in Miami, Fla. In three
centers, the percentages of Peni plus Penr were #10, eight
centers had percentages of 11 to 20, nine centers had percent-
ages of 21 to 30, six centers had percentages of 31 to 40, and
the remaining four centers had percentages of 41 to 53. Per-
centages of Peni varied between 2.1 and 29.6; Penr percentages
ranged from 0 to 23.5. In general, the highest percentages of
Penr were observed in centers with the highest percentages of
Peni.
Six pediatric hospitals were included in this survey. Peni plus
Penr strains accounted for 30.9% of isolates in these institu-
tions compared with 21.7% in the remaining 24 primarily adult
hospitals (P , 0.005). This is consistent with the values shown
in Tables 2 and 3 where rates of penicillin resistance were
sorted by patient age and specimen type. The highest rates of
resistance were observed in isolates from patients of #5 years
of age and from specimens representative of predominantly
childhood diseases (i.e., middle ear fluid and sinus aspirates).
Results obtained with 22 other antimicrobial agents are list-
ed in Table 4. Ampicillin appeared to be 1 twofold dilution less
active than penicillin for isolates of pneumococci irrespective
of penicillin susceptibility category. Amoxicillin and amoxicil-
lin-clavulanate were essentially identical in activity and rough-
ly equivalent to penicillin. Of the cephalosporins tested and
compared solely on the basis of MIC values, there emerged a
clear rank order of in vitro activity: cefotaxime5 ceftriaxone$
cefpodoxime $ cefuroxime . cefprozil $ cefixime . cefaclor
5 loracarbef . cefadroxil 5 cephalexin.
By comparing the geometric-mean MICs obtained with a
given cephalosporin for Pens strains of pneumococci versus the
geometric-mean MICs obtained with the same antimicrobial
agent for Peni and Penr strains, the relative influences of the
PBP alterations responsible for the two levels of penicillin
resistance on cephalosporin activity could be compared (Table
4). The magnitude of increase of cephalosporin MICs as or-
ganisms went from Pens to Peni and from Peni to Penr varied
between 6- and 22-fold with individual antimicrobial agents.
Among the cephalosporins, resistance percentages were cal-
culated only for cefotaxime, ceftriaxone, and cefuroxime, as
these are the only agents for which the NCCLS has established
interpretive criteria for resistance versus S. pneumoniae (17).
Overall, 3, 5, and 12% of pneumococcal isolates were resistant
to these three antimicrobial agents, respectively. The percent-
ages of resistance among Pens, Peni, and Penr isolates were,
respectively, 0, 1, and 32% for cefotaxime; 0, 2, and 50% for
ceftriaxone; and 0.4, 36, and 100% for cefuroxime.
Rifampin activity was comparable among Pens, Peni, and
Penr strains, with a total of 7 (0.5%) strains resistant to ri-
fampin (i.e., MICs of $4 mg/ml) (Table 4). Similarly, no dif-
ference in activity was noted with vancomycin and quinopris-
tin-dalfopristin among the three groups of pneumococci, with
vancomycin being ca. fourfold more active than the combina-
tion. No vancomycin resistance was observed. The frequency of
resistance with quinopristin-dalfopristin could not be calcu-
lated because of the absence of accepted MIC breakpoints for
pneumococci.
The rank order of relative in vitro activities of the three
macrolides examined in this study for the pneumococcus was
clarithromycin$ erythromycin$ azithromycin (Table 4) when
MIC50s (MICs at which 50% of the isolates are inhibited),
MIC90s, and geometric-mean MICs were compared. In terms
of overall prevalence of resistance, however, the macrolides
appeared equivalent, with 10% of all study isolates found to be
resistant to all three agents. Similar observations were made
when rates of macrolide resistance were compared with strains
in the three penicillin resistance categories. The resistance
percentages with all three macrolides were 4 with Pens strains,
19 to 20% with Peni isolates, and 49% with Penr isolates. There
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was near-complete cross-resistance among the three macro-
lides, with 97.6% of erythromycin-resistant strains also catego-
rized as being resistant to azithromycin and clarithromycin.
The overall percentages of strains resistant to chloramphen-
icol, tetracycline, and TMP-SMX were 4.3, 7.5, and 18, respec-
tively (Table 4). As was the case with the cephalosporins and
macrolides, the resistance percentages with these agents were
always higher with Peni isolates than with Pens strains and
highest with Penr organisms. The resistance percentages
among Pens, Peni, and Penr isolates were, respectively, 1, 7,
and 32 with chloramphenicol, 0.3, 17, and 43 with tetracycline
and 6, 40, and 80 with TMP-SMX.
Multiresistant strains are depicted in Table 5. A total of 138
study isolates (9.1%) were noted to be multiresistant when mul-
tiresistance was defined as Peni (n 5 49) or Penr (n 5 89) plus
resistance to at least two of the following compounds: erythro-
mycin, TMP-SMX, chloramphenicol and/or tetracycline. Two
patterns of resistance were apparent among the multiresistant
strains. Nearly all chloramphenicol-resistant strains were also
resistant to either tetracycline (i.e., 61 of 67 [91%]) and/or TMP-
SMX (i.e., 54 of 67 [80.6%]). The large majority of strains that
were resistant to at least three if not all four of these non-b-
lactam agents were also Penr, i.e., 58 of 79 (73.4%).
DISCUSSION
It is apparent from the results of this prospective national
30-center surveillance study that penicillin resistance with out-
patient isolates of S. pneumoniae has emerged as a major
problem in the United States. Although the percentages of
Peni and Penr strains varied significant among different med-
ical centers, the overall national percentage was 23.6, with
approximately two of every five nonsusceptible strains mani-
festing Penr. As has been reported by others, the highest rates
of penicillin resistance were noted with pneumococci from
pediatric patients, in particular, those with infections such as
otitis media or sinusitis, i.e., conditions often associated with
extensive exposure to oral b-lactam antimicrobial agents and
the resulting selective pressure (5, 14, 18). Both Peni and Penr
strains were also, however, frequently recovered from adults in
the present study, as has been previously reported (19).
Two previous multicenter national surveillance studies have
been conducted in the United States since 1990, i.e., the period
during which penicillin-resistant pneumococci apparently
emerged as a major problem (2, 24). The first study, in 1991 to
1992, found 15.2% Peni and 2.6% Penr strains (24). The sec-
ond study, in 1992 to 1993, observed percentages of 13.9 and
TABLE 1. Recovery of penicillin-resistant S. pneumoniae from 30 U.S. medical centers during 1994 and 1995
Medical center Location Total no.of isolates
No. (%) of isolates that were penicillin:
Susceptible Intermediate Resistant
Children’s Hospital Boston, Mass. 36 26 (72.2) 2 (5.6) 8 (22.2)
University of Massachusetts Medical Center Worcester, Mass. 30 25 (83.3) 4 (13.3) 1 (3.3)
Hartford Hospital Hartford, Conn. 61 55 (90.2) 3 (4.9) 3 (4.9)
SUNY Medical Center Syracuse, N.Y. 23 21 (91.3) 2 (8.7) 0 (0.0)
Strong Memorial Hospital Rochester, N.Y. 58 52 (89.7) 3 (5.2) 3 (5.2)
Columbia-Presbyterian Hospital New York, N.Y. 64 56 (87.5) 4 (6.3) 4 (6.3)
Temple University Medical Center Philadelphia, Pa. 47 46 (97.9) 1 (2.1) 0 (0.0)
Geisinger Medical Center Danville, Pa. 57 45 (78.9) 6 (10.5) 6 (10.5)
National Children’s Hospital Washington, D.C. 60 46 (76.7) 10 (16.5) 4 (6.7)
University of North Carolina Medical Center Chapel Hill, N.C. 60 40 (66.7) 14 (23.3) 6 (10.0)
DeKalb General Hospital Decateur, Ga. 61 40 (65.6) 9 (14.8) 12 (19.7)
Mt. Sinai Hospital Miami, Fla. 17 8 (47.1) 5 (29.4) 4 (23.5)
University of South Alabama Medical Center Mobile, Ala. 68 54 (79.4) 9 (13.2) 5 (7.4)
Cleveland Clinic Cleveland, Ohio 42 34 (81.0) 2 (4.8) 6 (14.3)
Henry Ford Hospital Detroit, Mich. 63 51 (81.0) 11 (17.5) 1 (1.6)
Methodist Hospital Indianapolis, Ind. 63 50 (79.4) 11 (17.5) 2 (3.2)
Rush Presbyterian Medical Center Chicago, Ill. 41 26 (63.4) 9 (22.0) 6 (14.6)
Evanston Hospital Evanston, Ill. 49 42 (85.7) 5 (10.2) 2 (4.1)
Children’s Hospital Milwaukee, Wis. 65 43 (66.2) 13 (20.0) 9 (13.8)
Mayo Clinic Rochester, Minn. 35 24 (68.6) 7 (20.0) 4 (11.4)
Jewish Hospital St. Louis, Mo. 56 42 (75.0) 11 (19.6) 3 (5.4)
University of Texas SW Medical Center Dallas, Tex. 58 45 (77.6) 5 (8.6) 8 (13.8)
Texas Children’s Hospital Houston, Tex. 63 47 (74.6) 6 (9.5) 10 (15.9)
Denver General Hospital Denver, Colo. 62 53 (85.5) 7 (11.3) 2 (3.2)
Primary Children’s Hospital Salt Lake City, Utah 62 37 (59.7) 15 (24.2) 10 (16.1)
Good Samaritan Hospital Phoenix, Ariz. 57 34 (59.6) 12 (21.1) 11 (19.3)
Cedar’s Sinai Hospital Los Angeles, Calif. 27 15 (55.6) 8 (29.6) 4 (14.8)
Stanford University Medical Center Palo Alto, Calif. 44 37 (84.1) 5 (11.4) 2 (4.5)
Kaiser Medical Center Portland, Oreg. 61 48 (78.7) 9 (14.8) 4 (6.6)
Children’s Hospital Seattle, Wash. 37 24 (64.9) 8 (21.6) 5 (13.5)
Total 1,527 1,166 (76.4) 216 (14.1) 145 (9.5)
TABLE 2. Recovery of penicillin-resistant S. pneumoniae
from patients grouped by age
Age group
(yr)
Total no.
of isolates
No. (%) of isolates that were penicillin:
Susceptible Intermediate Resistant
0–5 501 362 (72.3) 76 (15.2) 63 (12.6)
6–10 53 43 (81.1) 6 (11.3) 4 (7.5)
11–20 52 38 (73.1) 10 (19.2) 4 (7.7)
21–50 356 284 (79.8) 43 (12.1) 29 (8.1)
.50 560 437 (78.0) 79 (14.1) 44 (7.8)
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7.3, respectively (2). The results of the current study indicate
that the prevalence of Peni and Penr strains of S. pneumoniae
continues to increase in the United States. Of perhaps even
greater concern is the observation that the relative proportion
of nonsusceptible strains composed of Penr organisms is also
increasing. Currently, ca. 40% of nonsusceptible isolates are
Penr. Obviously, this has major therapeutic implications inso-
far as Penr organisms are likely to be more refractory to man-
agement with penicillin irrespective of the infectious disease
condition with which they are associated and are also most
resistant to other b-lactam antimicrobial agents.
The results of this study also permit comparisons of the
activities of other b-lactam antimicrobial agents versus con-
temporary pneumococci. Ampicillin was consistently 1 twofold
dilution less active than penicillin. Amoxicillin and amoxicillin-
clavulanate appeared to be essentially comparable to penicillin
in activity. The enhanced activities of these two compounds
versus penicillin for Peni and Penr S. pneumoniae, as has been
previously described (22), was not observed in this study. Of
interest were observations pertaining to resistance percentages
with amoxicillin and amoxicillin-clavulanate against Penr strains,
i.e., 66 and 60, respectively. These values indicate that a rea-
sonably high percentage of Penr isolates of S. pneumoniae
would be categorized as being something other than resistant
to amoxicillin and amoxicillin-clavulanate according to current
NCCLS breakpoints (17). Indeed, application of current break-
points would give these two compounds the appearance of
being more active than cefuroxime and nearly as active as
cefotaxime and ceftriaxone against Penr organisms.
The cephalosporins could be separated into several groups
with respect to in vitro activity as expressed by MIC50s,
MIC90s, and geometric-mean MICs. Two oral agents, cepha-
lexin and cefadroxil, had limited activity even for Pens S. pneu-
moniae. Three other oral cephalosporins, loracarbef, cefaclor,
and cefixime, were generally active only against Pens strains.
One agent, cefprozil, demonstrated at least modest activity
versus Peni isolates in addition to being uniformly active
against Pens strains. Two cephalosporins, cefuroxime and cef-
podoxime, were, like cefprozil, active against Pens strains but
demonstrated greater activity than cefprozil against Peni iso-
lates. All three of these agents lacked activity against Penr
isolates. Finally, two parenteral expanded-spectrum cephalo-
sporins, cefotaxime and ceftriaxone, were nearly uniformly ac-
tive against both the Pens and Peni strains and demonstrated at
least some activity against Penr strains.
Resistance to cefotaxime and ceftriaxone has previously
been described with S. pneumoniae (4, 7, 20). It has typically
been observed with Peni strains and has been noted to be the
TABLE 3. Recovery of penicillin-resistant S. pneumoniae from
different specimen types
Specimen Total no.of isolates
No. (%) of isolates that were penicillin:
Susceptible Intermediate Resistant
Middle ear fluid 118 68 (57.6) 26 (22.0) 24 (20.3)
Sinus aspirate 52 32 (61.5) 8 (15.4) 12 (23.1)
Conjuctival 105 93 (88.6) 10 (9.5) 2 (1.9)
Sputum 633 475 (75.0) 93 (14.7) 65 (10.3)
Blood 541 437 (80.8) 69 (15.8) 35 (6.5)
Cerebrospinal fluid 31 26 (83.9) 2 (7.7) 3 (9.7)
Other 43 31 (72.1) 8 (25.8) 4 (9.3)
TABLE 4. In vitro activities of 23 antimicrobial agents for 1,527 outpatient isolates of S. pneumoniaea
Antimicrobial
agent
Penicillin-susceptible strains
(n 5 1,165)
Penicillin-intermediate strains
(n 5 216)
Penicillin-resistant strains
(n 5 145)
All strains
(n 5 1,527)
MIC50 MIC90
Range of
MICs
Mean
MICb MIC50 MIC90
Range of
MICs
Mean
MIC MIC50 MIC90
Range of
MICs
Mean
MIC MIC50 MIC90
Penicillin 0.015 0.03 #0.004–0.06 0.03 0.25 1 0.12–1 0.33 2 4 2–8 2.4 0.015 1
Ampicillin 0.034 0.06 #0.008–1 0.03 0.5 2 0.06–4 0.51 4 8 2–16 4.0 0.03 2
Amoxicillin 0.015 0.03 ,0.004–0.12 0.015 0.25 1 0.03–4 0.25 2 8 1–8 2.0 0.015 1
Amox-clavc 0.015 0.03 ,0.004–1 0.015 0.25 1 0.03–4 0.25 2 4 1–8 2.0 0.015 1
Cefotaxime 0.015 0.06 ,0.004–1 0.015 0.25 1 0.015–4 0.20 1 4 0.5–8 1.42 0.015 1
Ceftriaxone 0.03 0.06 #0.004–1 0.024 0.25 1 0.008–4 0.25 2 4 0.5–8 1.46 0.03 1
Cefpodoxime 0.03 0.06 #0.015–4 0.04 0.5 2 0.03–.16 0.58 4 16 1–.16 4.75 0.03 2
Cefuroxime 0.03 0.12 #0.015–8 0.04 0.5 4 0.003–16 0.86 8 16 2–32 7.9 0.03 4
Cefprozil 0.25 0.25 #0.03–16 0.20 1 8 0.12–32 1.5 16 32 4–64 18 0.25 8
Cefixime 0.25 0.5 #0.06–32 0.31 4 16 0.12–128 3.5 32 64 8–.128 30 0.25 16
Cefaclor 0.5 1 #0.06–128 0.71 4 64 0.12–.128 5.0 128 .128 16–.256 109 1 64
Loracarbef 1 2 #0.06–128 1.0 8 64 0.5–.128 6.3 128 .128 8–.128 83 1 16
Cefadroxil 1 2 #0.12–128 1.6 8 64 0.5–256 10.3 64 256 16–.256 145 2 64
Cephalexin 2 4 #0.12–128 2.0 16 128 0.25–.256 14.2 128 .256 32–.256 141 2 128
Rifampin 0.03 0.06 #0.015–.32 0.03 0.03 0.06 #0.015–$32 0.03 0.03 0.06 #0.015–8 0.03 0.03 0.06
Vancomycin 0.25 0.5 #0.015–1 0.35 0.25 0.5 0.12–1 0.34 0.25 0.5 0.25–1 0.33 0.25 0.5
Quino-dalfod 1 2 0.12–4 0.97 1 2 0.25–8 1.2 1 2 0.5–4 1.2 1 2
Clarithromycin #0.03 0.06 #0.03–.64 0.03 #0.03 8 #0.03–.64 0.07 0.06 .64 #0.03–.64 2.0 #0.03 1
Erythromycin 0.06 0.06 #0.03–.64 0.06 0.06 8 #0.03–.64 0.10 0.12 .64 #0.03–.64 2.0 0.06 2
Azithromycin 0.12 0.12 #0.03–.64 0.11 0.12 8 #0.03–.64 0.23 0.25 .64 0.06–.64 3.5 0.12 2
Chloramphenicol 2 4 0.12–16 2.6 2 4 1–32 3.0 4 16 2–32 5.1 2 4
Tetracycline 0.12 0.25 #0.03–64 0.17 0.12 32 0.06–64 0.35 0.25 32 0.06–32 0.89 0.12 0.25
TMP-SMXe 0.25 1 #0.015–16 0.25 1 8 0.03–16 1.1 4 8 0.12–32 3.8 0.25 4
a All MICs given are in micrograms per milliliter.
b Geometric-mean MIC.
c Amox-clav, amoxicillin-clavulanate (2:1). The concentrations listed refer to amoxicillin.
d Quino-dalfo, quinopristin-dalfopristin (30:70). The concentrations listed refer to the total of the two streptogramins in the mixture.
e TMP-SMX, trimethoprim-sulfamethoxazole (1:19). The concentrations listed refer to trimethoprim.
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result of specific PBP alterations (7, 15). In the current study,
fully 3.2% (cefotaxime) and 5.1% (ceftriaxone) of all study
isolates had MICs of $2 mg/ml and thus were classified as
resistant according to the criteria of the NCCLS (17). There
was near-complete cross-resistance between these two agents,
to wit, all cefotaxime-resistant isolates were also ceftriaxone
resistant. Among the 1.9% of strains that were resistant to
ceftriaxone but not resistant to cefotaxime, all but one had
cefotaxime MICs of 1.0 mg/ml. The remaining isolate had a
cefotaxime MIC of 0.5 mg/ml. It is not clear whether these
apparent slight differences in activity between cefotaxime and
ceftriaxone represent anything more than subtle in vitro dif-
ferences in antibacterial effect. It is unlikely that they translate
into meaningful differences in clinical utility. Also of interest in
this study was the finding that the vast majority of strains
resistant to cefotaxime and ceftriaxone were Penr, not Peni.
For instance, among the total of 49 cefotaxime-resistant
strains, 2 were Peni while 47 were Penr. Ceftriaxone resistance
was observed with 78 isolates; 5 were Peni, and 73 were Penr.
One final observation concerning the activity of cephalospo-
rins versus S. pneumoniae today in the United States pertains
to the extent to which the activity of specific agents decreases
for Peni and Penr strains versus Pens isolates. The drop in
activity between Pens and Peni strains was 6- to 22-fold, de-
pending on the individual cephalosporin considered. The same
observation could be made of the cephalosporins when activity
versus Penr strains was compared with the activity against Peni
strains. Another 6- to 22-fold decrease in activity was observed.
This information together with knowledge of the intrinsic ac-
tivity of a particular cephalosporin versus Pens strains permits
reasonably accurate predictions of the activity of that agent for
Peni and Penr strains.
The three macrolides examined in this study, clarithromycin,
erythromycin, and azithromycin, were characterized by com-
parable overall percentages of resistance of 10. The overall
percentages of chloramphenicol, tetracycline, and TMP-SMX
resistance were 4.3, 7.5, and 18, respectively. The percentages
of resistance with all four of these antibiotic classes were sig-
nificantly higher with Penr strains than with Peni isolates. Re-
sistance was uncommon among Pens organisms. Clearly, as has
been described previously, resistance to non-b-lactam agents,
although mechanistically unrelated to penicillin resistance, oc-
curs most commonly in the United States in strains of S. pneu-
moniae that are also b-lactam resistant (2, 21). Of significance
was the observation that 9.1% of isolates of S. pneumoniae in
this survey were Peni (3.2%) or Penr (5.9%) and also resistant
to at least two of the following four antibiotics or antibiotic
classes: macrolides, tetracycline, chloramphenicol, and TMP-
SMX. Such isolates are considered multiresistant (10). Indeed,
23 isolates from 18 different centers were Penr and resistant to
all four of the non-b-lactam agents noted above. Fourteen of
these 23 organisms were also resistant to cefotaxime and ceftri-
axone (MICs $2 mg/ml). Rifampin resistance (i.e., 0.5%) was
uncommon.
Among the agents examined in this study, vancomycin was
the only compound for which no resistant strains were recog-
nized (MIC50s and MIC90s, 1 and 2 mg/ml, respectively). The
quinopristin-dalfopristin combination was consistently active
over a narrow concentration range (i.e., 0.25 to 4 mg/ml) with
MIC50s, MIC90s, and geometric-mean MICs 4-fold higher than
those noted with vancomycin. However, in the absence of ac-
cepted interpretive criteria, rates of resistance could not be
calculated with this combination.
In conclusion, antimicrobial resistance has clearly emerged
as a very serious problem with S. pneumoniae in the United
States. By analogy based on experiences in other parts of the
world, this problem is likely to grow in the future.
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